Updated: Lykos cutting most of staff less than a week after FDA rejection
Lykos Therapeutics is cutting 75% of its staff following the FDA’s rejection last week of its MDMA-assisted therapy, the company said Thursday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
